AccessibilityHelp
Burning Rock Biotech logo

Burning Rock Biotech(NASDAQ) BNR

Market Cap$103.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-95%
5 Year-91%
1 Year+13%
1 Month-22%
$11.82
-10.79%
-1.43Today
Burning Rock Biotech last closing stock price
MetricPriceDate
Last closeUSD 11.822026-10-23
Burning Rock Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.37%USD 12.902026-10-16
1 month-21.59%USD 15.082026-09-23
3 month+32.07%USD 8.952026-07-24
Year to date-41.34%USD 20.152025-12-31
1 year+12.57%USD 10.502025-10-23
3 year+13.65%USD 10.402023-10-24
5 year-90.83%USD 128.902021-10-22
Since inception-95.2%USD 246.302020-06-12

Burning Rock Biotech Financials at a Glance

Market Cap

$103.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥500.78M

Net Income (TTM)

-CN¥68.05M

EPS (TTM)

-$0.91

P/E Ratio

-12.95

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$11.82

Volume

51,636.414

Open

$13.51

Previous Close

$11.82

Daily Range

$11.60 - $13.51

52-Week Range

$6.79 - $41.72

Estimated Earnings Date

Nov 17, 2026

BNR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Burning Rock Biotech

Burning Rock Biotech Limited is a leading provider of diagnostic solutions for cancer therapy selection, headquartered in Guangzhou, China. Established in 2014, the company utilizes next-generation sequencing technology to offer a diverse range of tests aimed at guiding therapeutic decisions for various cancer types.

Products and Services
  • OncoCompass IO: A liquid biopsy test for cancer therapy selection
  • OncoScreen IO: A comprehensive pan-cancer test for tissue samples
  • ColonCore: Assesses microsatellite instability and genetic mutations in gastrointestinal cancers
Growth Outlook
  • Strategic partnerships with major pharmaceutical companies enhance market reach
  • Increasing demand for personalized medicine drives growth in diagnostic testing
  • Expansion into new markets expected to boost revenue potential
Financial Highlights
  • Recent quarterly revenue of 134.91 million CNY, showing a significant increase
  • Gross profit margin of 72.58% indicates strong operational efficiency
  • Current ratio of 3.03 suggests robust liquidity position
Burning Rock Biotech Limited operates across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company’s flagship products are designed to provide critical insights into cancer treatment options, thereby improving patient outcomes. The strategic collaborations with industry leaders like Myriad Genetics and Oncocyte Corporation further solidify its position in the market. The growth outlook for Burning Rock is promising, driven by the rising demand for personalized medicine and the company's ongoing efforts to expand its product offerings and market presence. Recent financial performance reflects a strong gross profit margin, indicating effective cost management and operational efficiency. The liquidity position, as evidenced by a current ratio above 3, provides a solid foundation for future growth initiatives. Overall, Burning Rock Biotech Limited stands out as a key player in the medical diagnostics and research industry, with a focus on innovative solutions that cater to the evolving needs of cancer therapy selection.
AI Generated • Oct 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

667

CEO

Yu Sheng Han, MBA

Website

www.brbiotech.com

Headquarters

Guangzhou, GD 510005, CN

BNR Financials

Key Financial Metrics (TTM)

Gross Margin

74.55%

Operating Margin

-12.99%

Net Income Margin

-13.59%

Return on Equity

-12.97%

Return on Capital

-9.48%

Return on Assets

-9.06%

Earnings Yield

-7.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$103.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.79M

Volume

51.64K

Avg. Volume

30.62K

Financials (TTM)

Gross Profit

CN¥373.34M

Operating Income

-CN¥65.03M

EBITDA

-CN¥42.24M

Operating Cash Flow

-CN¥12.22M

Capital Expenditure

-CN¥5.25M

Free Cash Flow

-CN¥17.47M

Cash & ST Invst.

CN¥419.26M

Total Debt

CN¥45.13M

Burning Rock Biotech Performance Analysis

Burning Rock Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 83,644,4806.2%
20232023-12-31CNY 75,855,022-9.3%
20242024-12-31CNY 71,673,625-5.5%
20252025-12-31CNY 75,060,4304.7%
Burning Rock Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-11.4%
Q42025-12-31-4.0%
Q12026-03-31-14.5%
Q22026-06-3025.0%
Burning Rock Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -13.8817.1%
20232023-12-31CNY -9.01-35.1%
20242024-12-31CNY -4.68-48.1%
20252025-12-31CNY -0.72-84.5%
Burning Rock Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-73.3%
Q42025-12-315.8%
Q12026-03-31-15.6%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥134.91M

-9.2%

Gross Profit

CN¥97.92M

-9.4%

Gross Margin

72.58%

N/A

Market Cap

$103.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$155.69K

N/A

Employees

667

N/A

Net Income

-CN¥18.43M

-90.0%

EBITDA

-CN¥15.75M

-122.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥419.26M

-7.4%

Total Debt

CN¥45.13M

+15.3%

Accounts Receivable

CN¥182.61M

-10.8%

Inventory

CN¥34.14M

-40.9%

Long Term Debt

CN¥23.75M

+20.7%

Short Term Debt

CN¥21.38M

+9.9%

Return on Assets

-9.06%

N/A

Return on Invested Capital

-12.20%

N/A

Free Cash Flow

-CN¥22.35M

+49.6%

Operating Cash Flow

-CN¥22.35M

+49.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMNProMIS Neurosciences, Inc.
$8.34-7.13%
EKSOEkso Bionics Holdings, Inc.
$15.90-9.86%
AYTUAytu BioPharma, Inc.
$1.90-4.04%
ADVBAdvanced Biomed Inc. Common Stock
$3.17-8.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About BNR

What is the current price of Burning Rock Biotech?

Burning Rock Biotech is trading at $11.82 per share.

What is the 52-week range for Burning Rock Biotech?

Over the past 52 weeks, Burning Rock Biotech has traded between $6.79 and $41.72.

How much debt does Burning Rock Biotech have?

As of the most recent reporting period, Burning Rock Biotech reported total debt of CN¥6.65M.

How much cash does Burning Rock Biotech have on hand?

Burning Rock Biotech reported CN¥61.77M in cash and cash equivalents in its most recent financial results.

What is Burning Rock Biotech’s dividend yield?

Burning Rock Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services